[{"id":"02b59dda-a0bd-4079-9e1d-c7572a4affab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010564","created_at":"2021-08-18T14:53:29.281Z","updated_at":"2024-07-02T16:35:21.048Z","phase":"Phase 1","brief_title":"Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)","source_id_and_acronym":"NCT05010564","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD20 • CD19 • CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD20 • CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • autologous TriCAR T • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 07/17/2026","primary_completion_date":" 07/17/2026","study_txt":" Completion: 03/29/2040","study_completion_date":" 03/29/2040","last_update_posted":"2024-02-02"}]